PMID: 9534838Apr 16, 1998Paper

Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine

The British Journal of Psychiatry : the Journal of Mental Science
B Sperner-UnterwegerW W Fleischhacker

Abstract

A 17-year-old boy suffering from a severe schizophrenic disorder of the paranoid type and mental retardation did not respond to treatment with typical antipsychotics, whereas under clozapine treatment he showed a favourable response. Discontinuation of clozapine led to an acute psychotic relapse. During clozapine treatment the patient developed severe neutropenia. Due to the history of unsatisfactory response to traditional antipsychotics, clozapine treatment was continued despite white blood cell (WBC) decline. Concomitant treatment with G-CSF was followed by a rapid normalisation of WBC. This case report is not intended to challenge the clinical practice of discontinuing clozapine upon the development of neutropenia/agranulocytosis, but rather to stimulate further research in the pathophysiology and clinical consequences of a clozapine rechallenge after a WBC decline, especially in patients with a rather complex symptomatology where no sufficient therapeutic results can be achieved with any other pharmacological intervention than clozapine.

References

May 23, 1992·Lancet·A Z SaffermanA Howard
Jul 15, 1993·The New England Journal of Medicine·J M AlvirJ A Schaaf
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D J GirlingR J Stephens

❮ Previous
Next ❯

Citations

Jan 22, 2005·European Journal of Clinical Pharmacology·David EspositoFrédéric Limosin
May 10, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Péter GasznerPiroska Kosza
Sep 13, 2000·Research in Developmental Disabilities·J L MatsonJ R Logan
Dec 4, 2003·Journal of Child and Adolescent Psychopharmacology·Alexandra SpornJudith L Rapoport
Mar 2, 2005·Journal of Clinical Psychopharmacology·Joyce G SmallJeffrey J Kellams
May 7, 2005·Journal of Clinical Psychopharmacology·Carlo MarchesiCarlo Maggini
Apr 19, 2003·International Clinical Psychopharmacology·Staffan HäggOlav Spigset
Nov 16, 2007·Journal of Clinical Psychopharmacology·Karen A Mathewson, J-P Lindenmayer
Jun 4, 2010·Journal of Clinical Psychopharmacology·Narsimha R PinnintiEileen McNeill Strouse
Jan 8, 2003·Psychosomatics·Oliver Freudenreich, Theodore A Stern
May 14, 2008·Southern Medical Journal·Tricia G Majczenko, Jonathan T Stewart
Jul 9, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tiziana FrieriVincenzo Villari
Aug 18, 2004·Journal of Intellectual Disability Research : JIDR·S ThalayasingamI Singh
May 22, 2009·American Journal of Hematology·Daniel TesfaJan Palmblad
Dec 27, 2005·Human Psychopharmacology·Giampaolo La MalfaAlessandro Castellani
Dec 25, 2004·Medical Hypotheses·S Ratna, P S R K Sastry
Jul 14, 2005·Expert Opinion on Drug Safety·Joanna FitzsimonsSeetal Dodd
Feb 12, 2013·General Hospital Psychiatry·Andreia W P HazewinkelErik J Giltay
Oct 31, 2002·Human Psychopharmacology·Cristiana SilvestriniPaola Pancheri
Apr 13, 2004·International Clinical Psychopharmacology·Yong Min AhnYong Sik Kim
Dec 10, 2014·Therapeutic Advances in Psychopharmacology·Nazife Gamze UstaAlaattin Duran
Sep 26, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Eric C KutscherRyan M Carnahan
Aug 3, 2001·The British Journal of Psychiatry : the Journal of Mental Science·P ConusP Baumann
Aug 18, 2017·Journal of Clinical Psychopharmacology·John LallyJames H MacCabe
Mar 6, 2018·American Journal of Therapeutics·Peter ManuJimmi Nielsen
Mar 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Louisa R DunkChristopher D Andrews
Jan 11, 2013·Clinical Schizophrenia & Related Psychoses·Michele Hill, Oliver Freudenreich

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Related Papers

The British Journal of Psychiatry : the Journal of Mental Science
P ConusP Baumann
The British Journal of Psychiatry : the Journal of Mental Science
Louisa R DunkChristopher D Andrews
Psychiatric Services : a Journal of the American Psychiatric Association
P R Miller
© 2022 Meta ULC. All rights reserved